Cancer Therapies Office Reorganized >> NCI Cancer Bulletin for September 20, 2011 - National Cancer Institute

 

Cancer Therapies Office Reorganized

The Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) announced the reorganization of its Office of Oncology Drug Products last week. The reorganized and renamed Office of Hematology and Oncology Products (OHOP) now consists of four divisions organized primarily by disease site.

The Division of Oncology Products 1 is responsible for reviewing therapies for breast, gynecologic, and genitourinary cancers, as well as supportive care for nonhematologic cancers.

The Division of Oncology Products 2 is responsible for reviewing therapies related to gastrointestinal, lung, head and neck, neurologic, and rare cancers, as well as pediatric solid tumors, melanoma, and sarcoma.

The Division of Hematology Products is responsible for adult and pediatric blood cancers, and the Division of Hematology Oncology Toxicology will review nonclinical pharmacology and toxicology issues related to cancer therapies.

OHOP will be directed by Dr. Richard Pazdur, who headed the Office of Oncology Drug Products. The reorganization “aligns FDA with the organizational structure of leading cancer treatment centers, academic programs, and the National Cancer Institute,” Dr. Pazdur said in a news release. The reorganization is expected to lead to “greater efficiencies” in the review process of cancer therapies, added CDER Director Dr. Janet Woodcock.
NCI Cancer Bulletin for September 20, 2011 - National Cancer Institute